Advertisement

FDA approves Gilead Science’s Truvada as first drug to reduce risk of sexually acquired HIV

WASHINGTON – The Food and Drug Administration has approved the first drug shown to reduce the risk of HIV infection, a milestone in the 30-year battle against the virus that causes AIDS.

The agency approved Gilead Sciences’ pill Truvada as a preventive measure for people who are at high risk of acquiring HIV, such as those who have sex with HIV-infected partners.

Breaking news from Canada and around the world sent to your email, as it happens.
For news impacting Canada and around the world, sign up for breaking news alerts delivered directly to you when they happen.

Get breaking National news

For news impacting Canada and around the world, sign up for breaking news alerts delivered directly to you when they happen.
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.

Gilead Sciences Inc. has marketed Truvada since 2004 as a treatment for people who are infected with the virus.

But company studies have shown the drug can prevent people from contracting HIV when used as a precautionary measure. A three-year study found that daily doses cut the risk of infection in healthy gay and bisexual men by 42 per cent, when accompanied by condoms and counselling.

 

Sponsored content

AdChoices